Royalty Pharma Inactive 10-Q2010 Q1 Quarterly report

Filed: 10 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acetate, acquired, agent, answered, area, asserted, ATM, awaiting, aware, bid, body, brand, centrally, CEO, Chancery, Channel, Civ, Civil, clarifying, Clomid, cognitive, Complaint, confidential, confirmation, consent, cream, creditor, CRO, customary, default, deliberately, desire, deterioration, discovery, discretion, distinguished, dog, dollar, drop, enable, erectile, escalating, estrogen, evidence, failed, fall, felt, FSH, gynecomastia, hormone, incidence, influence, Judicial, Ladenburg, Latin, LH, linked, memory, mental, mg, modify, motion, muscle, nasal, North, older, ophthalmologic, opined, paragraph, parallel, participated, percentage, physical, placement, prevalent, promulgated, protocol, purpose, readily, relegated, replace, replacement, Reserved, respond, retrospective, reverse, RPRX, screening, signaling, simply, Solvay, split, spray, stimulate, stimulation, suffer, superior, telapristone, Tennessee, Thalmann, therapeutic, therapy, tone, VASOMAX, VDG, vigorously, written

Removed: aging, AIHH, alternative, animal, closing, committed, competitive, concomitant, cover, debt, defending, deficit, discontinued, encountered, enforcing, exclusive, exploring, FASB, feasibility, feedback, filing, final, Formulation, fourth, framework, frequently, functional, Gedeon, holding, hypogonadotrophic, idiopathic, implementation, increased, intellectual, lipid, listed, marketable, measuring, moved, National, NIH, nonfinancial, objective, obligated, plasma, prepaid, produced, prosecuting, reflect, returned, Richter, satisfy, security, seeking, standard, submit, terminated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Royalty Pharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kathi A. Anderson, Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 10, 2010	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Accounting Officer
	Repros Therapeutics Inc.

A signed original of this written statement required by Section 906 has been provided to Repros and will be retained by Repros and furnished to the Securities and Exchange Commission or its staff upon request.